Navigating Pharmaceutical Marketing to Patients in an Evolving Privacy Landscape
Adapting Strategies for Compliance and Effective Patient Outreach Amid Expanding State Privacy Legislation
Marketing to patients in the life sciences industry has never been simple, and today, it’s becoming more nuanced than ever. A wave of state-level privacy legislation is reshaping how patient data can be used for outreach, requiring marketers to be more deliberate, transparent, and strategic. Based on experience working with patient engagement solutions, these changes are increasingly shaping how marketers approach outreach in practice. This perspective is intended for general informational purposes and does not constitute legal advice.
Although the evolving privacy landscape introduces complexity, it also reinforces something many of us already know: when patients knowingly opt in and receive meaningful value in return, engagement improves. In that sense, privacy reform is not only a compliance consideration, it can also be a performance advantage when approached thoughtfully.
- The Changing Privacy Landscape
HIPAA continues to regulate protected health information (PHI) when handled by covered entities and their business associates. However, HIPAA does not extend to many types of health-related data collected outside traditional healthcare environments, such as certain digital platforms and consumer-facing applications (hhs.gov).
To address perceived gaps, several states have enacted comprehensive privacy laws. The Washington My Health My Data Act (WMHMDA), passed in 2023, is one of the first laws specifically designed to protect consumer health data beyond HIPAA. It requires clear, affirmative consent for certain data collection and sharing practices and grants consumers rights related to access, deletion, and withdrawal of consent. Importantly, it applies broadly to entities doing business in or targeting residents of Washington (atg.wa.gov).
Other state laws include California’s CCPA/CPRA, Virginia’s VCDPA, Colorado’s CPA, and Connecticut’s CTDPA which regulate targeted advertising, data sales or sharing, and sensitive data processing. Because definitions and requirements vary by state, pharmaceutical marketers must evaluate campaigns through a state-by-state lens.
- What This Means for Patient Marketing
In practice, these developments mean:
- Campaign structures may need to account for geographic differences in consent and opt-out requirements.
- Using health-related or sensitive data for targeted advertising may require explicit opt-in consent depending on applicable state laws and specific use cases.
- Cross-site retargeting and third-party data enrichment strategies may introduce additional compliance considerations depending on how data is collected, processed, and disclosed.
- Marketing and legal teams must work closely with media and data partners to validate consent and data provenance.
As a result, express-consent channels where patients knowingly agree to receive communications are becoming central to sustainable outreach strategies.
- Compliant Marketing Pathways in a Privacy-First Environment
While some approaches may require enhanced consent and transparency mechanisms, there are several viable and compliant ways to reach patients:
- First-party, consent-based engagement models, such as branded sites, patient support programs, or co-pay programs.
- HIPAA-compliant authorizations obtained when marketing intentions are properly disclosed and documented.
- Point-of-care and contextual advertising that aligns sponsored content with a patient’s current healthcare experience rather than cross-site behavioral tracking.
Conversely, undisclosed third-party data usage, unauthorized processing of sensitive health data, or behavioral retargeting without proper notice and consent may present increased regulatory risk depending on jurisdictions and implementation.
- Strategic Tradeoffs and Evaluating Partners
Stricter privacy standards require marketers to think differently about scale versus quality. Express-consent audiences may be smaller, but they are typically more engaged and more qualified.
When evaluating partners, it can be helpful to look beyond reach and ask:
- How is consent obtained, and is it clear and affirmative?
- What types of data are used (clinical, behavioral, demographic), and is it based on claims data or real-time data?
- How is consent documented, refreshed, and revoked?
- What are the opt-in rates and equally important, the stay-in rates?
- What engagement and audience quality metrics are available?
In my experience, the nature of the opt-in matters. Behavioral consent used for modeled segments offers a different level of precision than data that originates from direct patient interaction or clinician-entered information. Regardless of the source, data usage must align with applicable consent requirements, regulatory expectations, and contractual safeguards.
- Consent-Driven Engagement in Practice
In working with consent-based patient engagement solutions, I have seen how patients respond when engagement is transparent and value driven. For example, 95% of patients report trusting the information presented within a patient portal, and opt-in and stay-in rates reach over 98%.
Patients who actively opt in to receive personalized health information within trusted digital healthcare environments consistently demonstrate stronger engagement compared to traditional passive digital approaches. In my experience, I have seen solutions like this deliver higher click-through performance compared to standard digital benchmarks, along with improvements in audience quality driven by clinically informed data inputs.
What sustains that engagement is not simply the act of opting in, it’s what follows. When patients receive condition-relevant education, contextually aligned sponsored content, and tools that support their healthcare journey, they are more likely to stay engaged over time.
Conclusion
The privacy landscape is undeniably reshaping pharmaceutical marketing. While the regulatory environment continues to evolve, the broader shift toward transparency and patient choice ultimately strengthens trust. In practice, this shift reinforces the value of engaging patients within trusted, consent-driven environments where relevance and timing matter.
By prioritizing clear consent, responsible data stewardship, and meaningful patient value, marketers can remain compliant while building deeper, more effective connections with the audiences they serve.
